Follistim AQ is administered via subcutaneous injection (under the skin) using the Follistim Pen device. It is not available in oral form, as the active hormone would be destroyed in the digestive system. Your healthcare team, especially a fertility nurse, will provide thorough training on how to properly prepare and self-administer the injections at home.

• Preparation: The Follistim AQ cartridges are pre-filled and ready for use with the Follistim Pen.
  
  
• Injection Technique: You will be taught how to load the cartridge into the pen, select the correct dose, and inject the medication into areas like the abdomen or thigh.
  
  
• Rotation of Sites: It’s important to rotate injection sites to prevent skin irritation or tissue damage.
  
  
• Disposal: Proper disposal of needles and syringes in a sharps container is essential.
  
  
• Timing: Dosing is typically once daily, often at the same time each day, as directed by your doctor. The duration of treatment varies per cycle, typically for 7-14 days.
  
  

Follistim AQ works by directly supplementing the body’s natural FSH levels. In women, FSH is the hormone primarily responsible for stimulating the growth and development of ovarian follicles, which are small sacs in the ovaries that contain immature eggs. By injecting follitropin beta, Follistim AQ encourages these follicles to grow and mature. For ovulation induction, the aim is usually to mature one or two dominant follicles. In ART cycles, the goal is to stimulate multiple follicles to develop, leading to the retrieval of several mature eggs. In men, FSH is crucial for the function of Sertoli cells in the testes, which are responsible for supporting the development and maturation of sperm (spermatogenesis). Follistim AQ provides a controlled amount of FSH to optimize these processes, increasing the chances of successful conception.

• Mechanism: Provides exogenous FSH to mimic or supplement natural hormone.
• In Women: Stimulates growth and maturation of ovarian follicles.
• In Men: Supports Sertoli cells for sperm production.
• Outcome: Promotes egg development for ovulation or retrieval, and sperm maturation.

Like all powerful medications, Follistim AQ can cause side effects, although not everyone experiences them.

• Common Side Effects: These are often mild and include injection site reactions (pain, redness, bruising, swelling, irritation), headache, nausea, fatigue, and pelvic discomfort or pain.
• Serious Side Effects (Women):
  • Ovarian Hyperstimulation Syndrome (OHSS): This is the most serious risk. It involves the ovaries becoming overstimulated, leading to enlargement, abdominal pain, bloating, nausea, vomiting, rapid weight gain, and in severe cases, fluid accumulation in the abdomen/chest, kidney problems, and blood clots.
  • Multiple Pregnancies: Follistim AQ significantly increases the chance of conceiving twins, triplets, or more, which carries higher risks for both mother and babies.
  • Ectopic Pregnancy: While related to the underlying infertility, the incidence may be higher in ART cycles.
  • Blood Clots: Rare, but serious, and can lead to conditions like stroke or pulmonary embolism.
  • Ovarian Torsion: Twisting of the ovary, a medical emergency.

Any severe or persistent side effects, especially symptoms of OHSS (severe abdominal pain, significant bloating, rapid weight gain, shortness of breath), should be reported to your doctor immediately.

• Common: Injection site reactions, headache, nausea, fatigue, pelvic discomfort.
• Serious (Women): Ovarian Hyperstimulation Syndrome (OHSS), multiple pregnancies, ectopic pregnancy, blood clots, ovarian torsion.
• Action: Immediate medical attention for severe symptoms, especially OHSS.

Before starting Follistim AQ, a comprehensive medical and gynecological/andrological evaluation by a fertility specialist is absolutely essential.

• Primary Ovarian/Testicular Failure: Follistim AQ is not effective if infertility is due to primary ovarian failure (meaning the ovaries cannot respond to FSH) or primary testicular failure. These conditions should be ruled out.
  
  
• Uncontrolled Endocrine Disorders: Pre-existing and uncontrolled thyroid or adrenal gland disorders, or pituitary/hypothalamic tumors, must be addressed before treatment.
  
  
• Undiagnosed Bleeding: Do not use if you have abnormal or heavy vaginal bleeding of unknown cause.
  
  
• Ovarian Cysts: Ovarian cysts not related to PCOS should be evaluated before starting treatment.
  
  
• Pregnancy/Breastfeeding: Follistim AQ is contraindicated in pregnant or breastfeeding women.
  
  
• Monitoring: Close monitoring with transvaginal ultrasounds (to track follicle growth) and blood tests (to measure hormone levels like estradiol) is crucial during treatment to guide dosing and minimize the risk of OHSS and multiple pregnancies.
  
  
• Risk Discussion: Your doctor will discuss the increased risks of multiple pregnancies, OHSS, and potential long-term risks (e.g., ovarian cancer, though direct causality is not fully established) before you begin treatment.
  
  
• Pre-treatment Evaluation: Essential to rule out primary organ failure, uncontrolled endocrine issues, and other contraindications.
  
  
• Monitoring: Critical for safety and efficacy (ultrasound, blood tests).
  
  
• Risk Awareness: Be fully informed about OHSS, multiple pregnancies, and other potential risks.
  
  

Immediate Reporting: Any concerning symptoms during treatment require prompt medical attention.

It’s crucial to inform your fertility specialist about all medications, supplements, and herbal products you are currently taking before starting Follistim AQ. While direct drug-to-drug interactions that significantly alter the effectiveness of Follistim AQ itself are not common in the same way as some oral medications, it’s almost always used as part of a complex treatment protocol with other fertility drugs.

• GnRH Agonists/Antagonists: These are frequently used alongside Follistim AQ to control the timing of ovulation or prevent premature ovulation. They do not directly interact but are part of a coordinated regimen.
  
  
• Hormonal Contraceptives: Birth control pills or other hormonal contraceptives would interfere with Follistim AQ’s action by suppressing natural hormone cycles and must be discontinued before treatment.
  
  
• Uncontrolled Endocrine Disorders: Existing and uncontrolled thyroid or adrenal gland disorders can impact fertility and the effectiveness of Follistim AQ; these must be managed before starting treatment.
  
  
• Other Fertility Medications: Simultaneous use of other gonadotropins or fertility drugs needs careful consideration and dose adjustment by your specialist.
  
  
• Key Co-medications: Often used with GnRH agonists/antagonists to manage ovulation timing.
  
  
• Interfering Medications: Hormonal contraceptives.
  
  
• Underlying Conditions: Uncontrolled thyroid/adrenal disorders can affect efficacy.
  
  
• Full Disclosure: Always provide a comprehensive list of all current medications to your doctor.
  
  

The dosage of Follistim AQ is highly individualized and meticulously determined by your fertility specialist. It depends on various factors, including:

• Specific Infertility Diagnosis: Whether for ovulation induction or ART.
  
  
• Patient’s Age and Body Weight.
  
  
• Ovarian Reserve/Testicular Function.
  
  
• Response to Previous Cycles: If applicable.
  
  
• Concomitant Medications: Used as part of the protocol.
  
  
• For Anovulatory Women (Ovulation Induction): A common starting dose is 50-75 IU (International Units) daily for at least 7 days, adjusted weekly based on ovarian response (follicle growth and estradiol levels), with a typical maximum of 250 IU/day.
  
  
• For ART (Controlled Ovarian Stimulation): Initial doses typically range from 150-225 IU daily, adjusted every few days based on monitoring, with a maximum of 450 IU/day.
  
  
• For Men (Spermatogenesis): Often used in conjunction with hCG, with specific protocols involving 225 IU twice weekly or 150 IU three times weekly, after testosterone levels are normalized by hCG pretreatment.
  
  

The total duration of FSH treatment is typically 7-14 days per cycle, followed by an hCG injection to trigger ovulation once follicles reach adequate size. Always follow your doctor’s exact instructions and never self-adjust the dose.

• Individualized Dosing: Tailored by your fertility specialist.
• Common Starting Doses: 50-75 IU/day for ovulation induction; 150-225 IU/day for ART.
• Adjustments: Based on close monitoring (ultrasound, blood tests).
• Combination: Often followed by hCG to induce final maturation/ovulation.

Follistim AQ is a specialized medication that always requires a prescription from a licensed healthcare professional, almost exclusively a reproductive endocrinologist or fertility specialist. It is not available over-the-counter.

The strict prescription requirement is due to:

• Powerful Hormonal Effects: It directly manipulates reproductive hormones, which requires careful medical oversight.
• Complex Protocols: Fertility treatments involve intricate timing and combinations of medications.
• Significant Potential Side Effects: The risks of OHSS and multiple pregnancies necessitate vigilant monitoring by a medical team.
• Thorough Diagnostic Workup: Before prescribing, a detailed evaluation is performed to ensure the medication is appropriate and safe for the individual’s specific infertility diagnosis.
• Ongoing Monitoring: Throughout the treatment cycle, regular blood tests and ultrasounds are crucial for safety and efficacy, which only a specialist can manage.

Self-medicating or using Follistim AQ without continuous medical supervision is dangerous and strongly discouraged.

• Status: Always a prescription-only medication.
• Prescriber: Reproductive endocrinologist or fertility specialist.
• Rationale: Complex hormonal effects, potential for serious side effects (OHSS, multiple births), and necessity for close monitoring.
• Process: Requires comprehensive diagnostic evaluation and ongoing medical supervision.

1. What is Follistim AQ used for?

• Induction of ovulation in anovulatory women

• Controlled ovarian stimulation for assisted reproductive technologies (ART)

• Treatment of hypogonadotropic hypogonadism in men to stimulate sperm production

2. What drug class does it belong to? Gonadotropins (recombinant FSH).

3. Is it a controlled substance? No, it is not a controlled substance.

4. Is it available in generic form? No, Follistim AQ is a branded recombinant FSH product.

5. What strengths are available? Cartridges containing 300 IU, 600 IU, or 900 IU of follitropin beta.

6. How is it administered? Subcutaneous injection using a prefilled pen device.

7. What is the usual dosage?

• Women: Starting dose of 50 IU daily for 7 days, adjusted based on response

• Men: Typically 150 IU three times per week, often combined with hCG

8. What are common side effects? Abdominal pain, bloating, headache, injection site reactions, nausea.

9. Can it cause serious reactions? Yes—Ovarian Hyperstimulation Syndrome (OHSS), multiple births, thromboembolism, and allergic reactions.

10. Is it safe during pregnancy? No—contraindicated during pregnancy.

11. Is a prescription required? Yes, administered under specialist supervision.

12. Is it available in Pakistan? Yes, through fertility clinics and specialty pharmacies.

13. Can it be used with other fertility drugs? Yes—often combined with hCG, GnRH agonists/antagonists, or progesterone.

14. How is it stored? Refrigerated at 2–8°C; can be kept at room temperature (≤25°C) for up to 3 months.

15. What makes it different from urinary FSH products? Follistim AQ is recombinant, offering higher purity and consistent dosing.

16. Is it used in IVF protocols? Yes—commonly used for controlled ovarian stimulation.

17. Can men use Follistim AQ? Yes—for treating male infertility due to FSH deficiency.

18. What should be monitored during use? Estradiol levels, follicle growth via ultrasound, and signs of OHSS.

19. Is self-injection possible? Yes—with proper training using the Follistim Pen.

20. What are contraindications?

• Primary ovarian failure

• Uncontrolled thyroid/adrenal disorders

• Tumors of reproductive organs

• Pregnancy